26 Feb 2013 Posted in ABPI statement By Press Office
"The reforms will allow pharmaceutical companies to conduct clinical trials and health technology assessments for new medicines without infringing the patents of other medicines.
"This is a welcome development that will make the UK a more attractive place in which to conduct clinical trials, which in turn will encourage pharmaceutical companies to continue operating here. Ultimately, it is UK patients that have the most to gain, as they will benefit from the creation of more innovative new medicines.”
ABPI Press Office
Tel: +44 (0) 20 7747 1410
Mobile: +44 (0) 7850 312064
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.